Home > Boards > US Listed > Medical - Equipment > Tandem Diabetes Care Inc (TNDM)

Oppenheimer analyst Steven Lichtman maintained a Buy rating

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
[SMART MONEY]  Member Profile
Member Level 
Followed By 3,258
Posts 118,416
Boards Moderated 15
Alias Born 08/05/09
160x600 placeholder
Tandem Diabetes Care Announces Health Canada Approval of t:slim X2 Insulin Pump with Basal-IQ Predictive Low-Glucose Suspend ... Business Wire - 11/20/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2019 4:25:50 PM
Tandem Diabetes Care Announces Upcoming Conference Presentations Business Wire - 11/8/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/6/2019 5:14:20 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2019 4:20:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:15:01 PM
Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance Business Wire - 11/4/2019 4:05:00 PM
2019 Beyond Type Run Team to Race the TCS New York City Marathon Using Basal-IQ Technology from Tandem Diabetes Care Business Wire - 11/1/2019 4:15:00 PM
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technolog... Business Wire - 10/30/2019 4:05:00 PM
Tandem Diabetes Care Announces NEJM Publication of Landmark Study Demonstrating Increased Time-In-Range with the t:slim X2 In... Business Wire - 10/16/2019 5:15:00 PM
Tandem Diabetes Care Up 10%; To Work With Abbott Dow Jones News - 10/15/2019 10:45:00 AM
Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management PR Newswire (US) - 10/15/2019 8:00:00 AM
Tandem Diabetes Care to Announce Third Quarter 2019 Financial Results on November 4, 2019 Business Wire - 10/14/2019 4:05:00 PM
Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes ... Business Wire - 9/18/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 4:20:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2019 7:28:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2019 4:19:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/29/2019 7:31:35 PM
Tandem Diabetes Care Announces Upcoming Conference Participation and Presentations Business Wire - 8/29/2019 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/28/2019 4:10:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 4:13:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/13/2019 4:54:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2019 6:54:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2019 4:18:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2019 4:15:25 PM
[SMART MONEY] Member Level  Friday, 06/22/18 07:02:18 AM
Re: Woody Driver post# 236
Post # of 275 
Oppenheimer analyst Steven Lichtman maintained a Buy rating on Tandem Diabetes (NASDAQ: TNDM) today and set a price target of $24. The company’s shares closed yesterday at $20.31, close to its 52-week high of $21.50.


http://www.analystratings.com/articles/oppenheimer-sticks-to-its-buy-rating-for-tandem-diabetes/

Always consult an Investment Professional, my posts are my own
opinions, and not for investing decisions!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist